文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

COVID-19与静脉血栓栓塞风险:多样族裔住院人群研究

COVID-19 and Risk of VTE in Ethnically Diverse Populations.
PubMed 文献 · Chest · 2021-07-19
一句话结论住院COVID-19成人30天VTE风险较匹配对照高3.48倍(aHR 3.48,95%CI 2.03-5.98),需关注年龄≥55岁、黑人、既往VTE、脓毒症、中重度肝病、BMI≥40、血小板>217k/μL等高危特征。

这项回顾性研究来自两个整合医疗系统36家医院,纳入6,319例实验室确诊COVID-19住院成人与6,319例按年龄、性别、种族/族裔、急性病严重度和住院月份匹配的非COVID-19住院成人。30天随访中,COVID-19组VTE 160例、对照组153例,死亡分别为817例和355例。校正竞争风险死亡及组间残余差异后,COVID-19与VTE风险升高相关(aHR 3.48,95%CI 2.03-5.98)。COVID-19患者中VTE预测因素包括年龄≥55岁、黑人种族、既往VTE、诊断脓毒症、既往中重度肝病、BMI≥40 kg/m2、血小板计数>217 k/μL。

要点

  • 住院COVID-19成人30天VTE调整风险为匹配非COVID-19住院成人的3.48倍(95%CI 2.03-5.98)。
  • COVID-19患者VTE预测因素:年龄≥55岁、黑人种族、既往VTE、诊断脓毒症、既往中重度肝病、BMI≥40 kg/m2、血小板>217 k/μL。
  • 研究采用36家医院、6,319对匹配成人,按年龄、性别、种族/族裔、急性病严重度和住院月份匹配。
  • 30天随访COVID-19组死亡817例,对照组355例;VTE事件分别为160例和153例。
  • VTE通过诊断编码结合经电子健康记录验证的自然语言处理算法确认。

适用人群与场景

  • 住院成人,实验室确诊COVID-19,与无COVID-19证据的住院成人按年龄、性别、种族或族裔、急性病严重度、住院月份匹配。
  • 研究场景为两个整合医疗系统的36家医院,住院时间2020年1月至2020年8月。
  • 平均年龄60.0±17.2岁,46%女性,53.1%西班牙裔,14.6%亚裔/太平洋岛民,10.3%黑人。

诊断标准与关键阈值

  • VTE定义为DVT或肺栓塞,通过诊断编码结合经电子健康记录验证的自然语言处理算法确认。
  • COVID-19患者中VTE预测因素包括年龄≥55岁、黑人种族、既往VTE、诊断脓毒症、既往中重度肝病、BMI≥40 kg/m2、血小板计数>217 k/μL。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:回顾性研究,两个整合医疗系统36家医院,6,319例COVID-19住院成人与6,319例匹配非COVID-19住院成人。
  • 主要终点:30天VTE,COVID-19组160例,对照组153例;校正后COVID-19与VTE风险升高相关(aHR 3.48,95%CI 2.03-5.98)。
  • 30天全因死亡:COVID-19组817例,对照组355例。
  • COVID-19患者中VTE预测因素:年龄≥55岁、黑人种族、既往VTE、诊断脓毒症、既往中重度肝病、BMI≥40 kg/m2、血小板计数>217 k/μL。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:原文未明确列出局限;设计本身为回顾性、观察性研究,使用诊断编码和自然语言处理算法确认VTE。

对床旁实践的改变

  • 原文提示住院COVID-19成人VTE风险较匹配非COVID-19住院成人高3.48倍,应关注VTE风险。
  • 原文识别出的COVID-19患者VTE预测因素(年龄≥55岁、黑人种族、既往VTE、诊断脓毒症、既往中重度肝病、BMI≥40 kg/m2、血小板>217 k/μL)可用于风险分层参考。
  • 原文未提供预防或治疗剂量方案,不能据此改变抗凝具体用药。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Limited existing data suggest that the novel COVID-19 may increase risk of VTE, but information from large, ethnically diverse populations with appropriate control participants is lacking.

RESEARCH QUESTION: Does the rate of VTE among adults hospitalized with COVID-19 differ from matched hospitalized control participants without COVID-19?

STUDY DESIGN AND METHODS: We conducted a retrospective study among hospitalized adults with laboratory-confirmed COVID-19 and hospitalized adults without evidence of COVID-19 matched for age, sex, race or ethnicity, acute illness severity, and month of hospitalization between January 2020 and August 2020 from two integrated health care delivery systems with 36 hospitals. Outcomes included VTE (DVT or pulmonary embolism ascertained using diagnosis codes combined with validated natural language processing algorithms applied to electronic health records) and death resulting from any cause at 30 days. Fine and Gray hazards regression was performed to evaluate the association of COVID-19 with VTE after accounting for competing risk of death and residual differences between groups, as well as to identify predictors of VTE in patients with COVID-19.

RESULTS: We identified 6,319 adults with COVID-19 and 6,319 matched adults without COVID-19, with mean ± SD age of 60.0 ± 17.2 years, 46% women, 53.1% Hispanic, 14.6% Asian/Pacific Islander, and 10.3% Black. During 30-day follow-up, 313 validated cases of VTE (160 COVID-19, 153 control participants) and 1,172 deaths (817 in patients with COVID-19, 355 in control participants) occurred. Adults with COVID-19 showed a more than threefold adjusted risk of VTE (adjusted hazard ratio, 3.48; 95% CI, 2.03-5.98) compared with matched control participants. Predictors of VTE in patients with COVID-19 included age ≥ 55 years, Black race, prior VTE, diagnosed sepsis, prior moderate or severe liver disease, BMI ≥ 40 kg/m2, and platelet count > 217 k/μL.

INTERPRETATION: Among ethnically diverse hospitalized adults, COVID-19 infection increased the risk of VTE, and selected patient characteristics were associated with higher thromboembolic risk in the setting of COVID-19.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Go AS, Reynolds K, Tabada GH, et al. COVID-19 and Risk of VTE in Ethnically Diverse Populations. Chest. 2021. PMID: 34293316. doi:10.1016/j.chest.2021.07.025

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。